President Donald Trump has announced an ambitious initiative aimed at dramatically reducing prescription drug costs for Americans, characterizing the current pricing system as a “scam” that has forced U.S. consumers to subsidize lower drug prices around the world.
Targeting global price disparities
In a detailed policy address, Trump highlighted the striking differences between prescription drug prices in the United States and other developed nations. He cited examples including a breast cancer medication that costs American patients $16,000 while Swedish patients pay just $1,600 for the identical product manufactured by the same company in the same facility.
“For decades, Americans have unknowingly funded a system where they pay up to ten times more for prescription drugs than people in other European countries,” Trump stated, framing the issue as one of fundamental fairness for American consumers.
The scale of these disparities extends across numerous medications. According to data presented during Trump’s address, asthma treatments that cost approximately $500 in the U.S. are available for less than $40 in the United Kingdom, while popular weight-loss injections can be purchased abroad for roughly one-tenth of their American price.
“A scam for America’s beneficiaries”
Trump characterized the current pricing structure as “a scam for America’s beneficiaries,” suggesting that American patients have been unwittingly subsidizing lower drug costs for patients in other countries.
To illustrate the personal impact of these policies, Trump shared an anecdote from a supporter: “President, I just paid $88 for this fat drug I take. In New York, I paid $1,300. What the hell is going on?”
The president attributed these price differences to intentional design rather than market forces. He explained that foreign governments aggressively negotiate with pharmaceutical companies, essentially presenting an ultimatum: accept significantly lower prices or lose access to their markets entirely. Drug manufacturers, still seeking profits, then shift the cost burden to American consumers who lack similar bargaining protection.
Executive order to implement “most favored nations” policy
Trump’s proposed solution is what he describes as a “most favored nations” executive order that would align U.S. drug prices with those paid by the lowest-paying developed country for the same medications.
“If Australia gets a cancer drug for $100, then the U.S. will too,” Trump explained, estimating that implementation of this policy could “drop drug prices by 59–90% almost immediately.”
The approach represents a significant departure from previous justifications for the higher American prices, which often cited the need to fund pharmaceutical research and development. Trump’s counterargument suggests other countries should bear more of those costs rather than placing the entire financial burden on American consumers.
Political landscape and pharmaceutical influence
During a White House briefing on the proposal, Robert F. Kennedy Jr. voiced support for Trump’s initiative, noting, “Every major Democratic leader for 20 years made this promise to the American people.”
Kennedy went on to describe the substantial influence of pharmaceutical companies in Washington, stating, “Congress is controlled in so many ways by the pharmaceutical industry. There’s at least one pharmaceutical lobbyist for every congressman, every senator on Capitol Hill, and every member of the Supreme Court.”
Trump himself acknowledged the formidable obstacles to reform, observing that “the drug lobby is the strongest lobby in this country,” suggesting that previous reform efforts have been stymied by this powerful industry influence.
As the proposal moves forward, it faces potential challenges from both the pharmaceutical industry and legislative complexities, but represents one of the most aggressive attempts to address prescription drug pricing in recent years, with potential implications for millions of American consumers struggling with medication costs.
